首页> 外文期刊>Gene: An International Journal Focusing on Gene Cloning and Gene Structure and Function >Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient
【24h】

Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient

机译:改善了富含非小细胞肺癌患者恶性胸腔积液的肿瘤细胞EGFR突变的检测

获取原文
获取原文并翻译 | 示例
       

摘要

Abstract Previous studies focus on developing high sensitive PCR-related technologies to detect EGFR gene mutation in malignant pleural effusion (MPE) of non-small cell lung cancer patient (NSCLC) instead of improving the quality of clinical samples themselves. We therefore hypothesized that the enrichment of tumor cells in MPE could improve the quality of MPE for the more accurate detection of EGFR gene mutation in the patients with NSCLC. MPE were collected from 28 patients with NSCLC. The tumor cells in MPE were firstly enriched by the depletion of leukocytes with bi-antibodies and identified by multiple flow cytometry. CastPCR was performed to detect the deletions in exon 19 (DelEGFR19) and point mutations in 20 (T790M, c.2369C>T) and 21 (L858R, c.2573T>G) of EGFR. All the detected mutations were confirmed their presence by Sanger sequencing. Before enrichment, the tumor cells in MPE were detected in 46.4% (13/28) of samples and the median value of the percentage of the tumor cells was only 0.64% including 3 (10.7%, 3/28) of samples more than 10% on it. After enrichment, the tumor cells were detected in all samples (100%) and the median value of the percentage of tumor cells was increased to 40.8% including only one (3.6%, 1/28) less than 10% on it. EGFR gene mutations were detected in 28.6% (8/28) and 42.9% (12/28) of the samples before and after enrichment, respectively. The sensitivity on the detection rate was relatively increased by 44.4%. Moreover, the mutations can be confirmed their presence by Sanger sequencing in 6 samples before enrichment (75%, 6/8) and 11 samples (91.7%, 11/12) after enrichment. It is valuable to improve the quality of the sample by the enrichment of the tumor cells from MPE for the following genetic analysis. Graphical abstract Display Omitted Highlights ? After enrichment, the tumor cells were detected in all of the samples from MPE. ? After enrichment, the percentage of the tumor cells in MPE was increased from 0.64% (before enrichment) to 40.8%. ? The relative sensitivity on the detection of EGFR gene mutations was increased by 44.4% after the tumor cells enriched. ? The reliability on the detection of EGFR gene mutations was improved from 75% to 91.7% after the tumor cells enriched. ? A novel strategy was provided for the genetic analysis from MPE by improving the quality of the sample.
机译:摘要以前的研究重点是开发高敏感的PCR相关技术,以检测非小细胞肺癌患者的恶性胸腔积液(MPE)的EGFR基因突变,而不是改善临床样品的质量。因此,我们假设MPE中肿瘤细胞的富集可以提高MPE的质量,以便更准确地检测NSCLC患者的EGFR基因突变。从28例NSCLC患者收集MPE。首先通过用双抗体的白细胞耗竭首先富集MPE中的肿瘤细胞,并通过多种流式细胞术鉴定。进行CastPCR以检测EXON 19(DELEGFR19)和点突变中的缺失(T790M,C.2369C> T)和21(L858R,C.2573t> G)的EGFR的缺失。所有检测到的突变都被Sanger测序证实了它们的存在。在富集之前,在46.4%(13/28)的样品中检测MPE中的肿瘤细胞,肿瘤细胞百分比的中值仅为0.64%,其中包含超过10的样品3(10.7%,3/28)样品% 在上面。在富集后,在所有样品(100%)中检测到肿瘤细胞,肿瘤细胞百分比的中值增加至40.8%,其中仅在其上仅比10%小于10%。在富集之前和之后分别在28.6%(8/28)和42.9%(12/28)中检测到EGFR基因突变。检出率的敏感性相对较高44.4%。此外,可以在富集后(75%,6/8)和11个样品(75%,6/8)和11个样品(91.7%,11/12)在富集后的6个样品中的Sanger测序,突变证实它们的存在。通过从MPE中富集肿瘤细胞来提高样品的质量是有价值的,从而进行以下遗传分析。图形抽象显示省略了亮点?在富集后,在来自MPE的所有样品中检测到肿瘤细胞。还富集后,MPE中肿瘤细胞的百分比从0.64%(在富集)中增加至40.8%。还浓缩肿瘤细胞富集后,对EGFR基因突变检测的相对敏感性增加了44.4%。还在富集的肿瘤细胞后,对EGFR基因突变检测的可靠性从75%增加到91.7%。还通过改善样品的质量,为来自MPE的遗传分析提供了一种新的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号